On Wednesday 16 April, the European Commission announced that the previous day it had granted EU authorisation for Leqembi, a drug designed to treat mild cognitive impairment in the early stages of Alzheimer's disease.
Strict conditions have been laid down for the first drug of this type to be authorised in the European Union. However, this drug will only be available for a very specific category of Alzheimer’s patients, who are far from a majority.
The European Medicines Agency (EMA)...